How is bipolar disorder different from depression?

Unipolar major depression involves recurrent depressive episodes WITHOUT any manic or hypomanic episodes. Bipolar disorder involves both depressive episodes AND manic or hypomanic episodes. Distinguishing them is critically important: antidepressant monotherapy in bipolar disorder can precipitate mania, trigger rapid cycling and worsen the long-term course. A thorough lifetime mood history — specifically asking about previous periods of elevated/energised mood, reduced sleep need and impulsive behaviour — is essential at every depression assessment.

Why is bipolar disorder so often misdiagnosed?

Bipolar disorder is typically misdiagnosed as unipolar depression — for several reasons: patients typically present during a depressive episode (the dominant phase in most patients); hypomania may not be perceived as pathological by the patient or family; clinicians may not ask about prior hypomanic/manic episodes; and there are no biomarker tests. The average delay from first symptoms to correct diagnosis is 6-10 years — during which patients may receive antidepressant monotherapy that worsens their course.

What other treatments exist for bipolar disorder?

Mood stabilisers: valproate/valproic acid (highly effective for mania — but CANNOT be used in women of childbearing potential due to teratogenicity and adverse neurodevelopmental effects in exposed children; EU restrictions); lamotrigine (most effective bipolar antidepressant — prevents depressive episodes). Antipsychotics with mood stabilising properties: quetiapine (effective for both mania and depression); olanzapine; aripiprazole; cariprazine. Psychological treatments: CBT for bipolar, family-focused therapy, interpersonal and social rhythm therapy (IPSRT) — to regularise daily rhythms.

What is the suicide risk in bipolar disorder?

Bipolar disorder carries a 30-fold elevated suicide risk compared to the general population — one of the highest of any health condition. Lifetime suicide attempt rates reach 25-50% (vs 1-4% general population). Risk is highest in bipolar II (where severe depression is dominant) and during mixed states (simultaneous depressive and manic features — combining depressive hopelessness with manic energy and impulsivity). Lithium uniquely reduces suicide risk; clozapine is used in treatment-resistant suicidal bipolar disorder.

How does bipolar disorder affect the brain?

Progressive structural brain changes accompany bipolar disorder — including grey matter volume reductions in prefrontal cortex, amygdala and hippocampus — particularly with more episodes and longer duration. This supports the "neuroprogression" model: each episode causes measurable brain changes, reinforcing the importance of early diagnosis and sustained mood stabilisation to prevent accumulating damage. Lithium has been specifically shown to increase grey matter volume and may protect against this neuroprogression.

What is the difference between mania and hypomania?

Mania: symptoms lasting ≥7 days or severe enough to require hospitalisation; may include psychotic features (hallucinations, delusions); causes marked functional impairment; defines Bipolar I. Hypomania: manic symptoms lasting ≥4 days but NOT severe enough for hospitalisation; no psychotic features; causes some functional change noticed by others but not severe impairment; defines Bipolar II. The distinction is clinically important — hypomania may be experienced as productive or pleasurable, making Bipolar II harder to recognise.

Is bipolar disorder heritable?

Bipolar disorder has approximately 70-80% heritability — among the highest of any psychiatric condition. First-degree relatives of people with BD have a 5-10 fold elevated risk. Multiple common genetic variants (CACNA1C, ANK3, and others from GWAS) contribute modest risks. Concordance in identical twins is approximately 40-70% — indicating genetic but also important environmental and developmental contributions.

How does GMJ News cover bipolar disorder?

GMJ News covers WHO bipolar disorder burden data, lithium's unique suicide prevention evidence, the misdiagnosis problem, treatment access gaps and the neuroscience of bipolar disorder. Bipolar disorder management — including lithium access — is directly relevant to PHIG's mental health priorities and the Georgian Medical Journal.

Home › Topics › Bipolar Disorder

Bipolar Disorder

Q: What is bipolar disorder?

Bipolar disorder is a serious mental health condition characterised by episodes of mania (extreme elevated/irritable mood, decreased sleep, impulsive behaviour, grandiosity) alternating with episodes of depression. It affects approximately 45 million people globally and is among the leading causes of disability for young adults. Onset is typically before age 25 — with 70% of cases beginning before age 25. It is a spectrum from Bipolar I (full mania) through Bipolar II (hypomania + major depression) to cyclothymia.

Q: What is lithium and why is it so important?

Lithium carbonate — a naturally occurring salt — has been used in psychiatry since 1949 and remains the gold standard mood stabiliser for bipolar disorder. Its unique properties: most effective single agent for long-term prevention of both mania and depression; the only psychiatric medication proven to reduce suicide risk (5-fold reduction in suicide vs other treatments — Cipriani Cochrane review); neuroprotective effects (possibly increasing grey matter volume); and anti-inflammatory effects. It requires careful monitoring of blood levels, renal function and thyroid function.

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Bipolar disorder — characterised by episodes of mania or hypomania alternating with depression — affects approximately 45 million people globally and is among the leading causes of disability for young adults, with onset typically before age 25 (WHO). Despite having effective treatments — lithium (the only drug proven to reduce suicide risk), valproate, lamotrigine and atypical antipsychotics — the treatment gap in LMICs exceeds 75-80%, and even in high-income countries misdiagnosis as depression (leading to harmful antidepressant monotherapy) delays correct treatment by an average of 6-10 years.

Key messages

45 million people

Bipolar disorder affects approximately 45 million people globally — approximately 1-2% of the population — and is among the top 10 causes of disability for young adults, with onset typically before age 25 (WHO).

Misdiagnosed as depression

Bipolar disorder is misdiagnosed as unipolar depression in the majority of cases — leading to an average of 6-10 years before correct diagnosis. Antidepressant monotherapy without a mood stabiliser in bipolar disorder can trigger mania, rapid cycling and worsen outcomes.

Lithium — unique life-saving properties

Lithium carbonate — the oldest mood stabiliser — remains the gold standard treatment for bipolar disorder. Uniquely, it is the only psychiatric medication proven to reduce suicide risk by approximately 5-fold. It also has neuroprotective effects.

69% treatment gap in LMICs

More than 50% of people with bipolar disorder receive no treatment globally; in LMICs the treatment gap exceeds 69%. This represents one of the largest unmet needs in mental health care.

Suicide risk

Bipolar disorder carries a 30-fold elevated suicide risk vs the general population. Lifetime suicide attempt rates reach 25-50%. Suicide prevention is a core treatment goal — lithium is the primary pharmacological tool.

Spectrum condition

Bipolar disorder exists on a spectrum: Bipolar I (full manic episodes ± depression — most severe); Bipolar II (hypomanic episodes + major depression — not mild); cyclothymia (subthreshold fluctuations). Correct classification guides treatment.

Key statistics

45M

people with bipolar disorder globally

WHO

6-10yr

average delay to correct diagnosis

WHO/research

suicide risk reduction with lithium

Cipriani et al. Cochrane

30x

elevated suicide risk vs general population

WHO/Lancet

>50%

treatment gap globally

WHO

69%

treatment gap in LMICs

WHO

Bipolar disorder burden (DALYs per 100,000) by region — GBD 2019

Source: Global Burden of Disease 2019. Bipolar disorder burden is relatively consistent across world regions.

Glossary of key terms

Mania
WHO/DSM-5A distinct period of abnormally elevated, expansive or irritable mood + increased goal-directed activity/energy — lasting ≥7 days (or shorter if hospitalised). Plus ≥3 of: grandiosity, decreased sleep need, pressured speech, racing thoughts, distractibility, increased activity, risky behaviour. Diagnostic of Bipolar I.

Bipolar I disorder
WHO/DSM-5Defined by at least one manic episode (lasting ≥7 days or requiring hospitalisation). Depressive episodes common but not required for diagnosis. The most severe form of bipolar disorder. Requires mood stabilisers for maintenance.

Bipolar II disorder
WHO/DSM-5Defined by at least one hypomanic episode (manic symptoms lasting ≥4 days, not requiring hospitalisation) AND at least one major depressive episode — without ever having had a full manic episode. NOT a milder form — major depression predominates and causes significant disability.

Lithium carbonate
WHO EML/BAPThe gold standard mood stabiliser for bipolar disorder — the most effective agent for mania prevention, depressive episode prevention and suicide risk reduction. Requires monitoring of plasma levels, renal function and thyroid function. Narrow therapeutic window. On WHO Essential Medicines List.

Rapid cycling
WHO/DSM-5A specifier applied when a person has ≥4 mood episodes (mania, hypomania, depression or mixed) per year — associated with greater illness burden and worse treatment response. Often precipitated by antidepressant monotherapy in bipolar disorder.

Mood stabilisers
WHO/BAPMedications that prevent or reduce the severity of manic and/or depressive episodes in bipolar disorder: lithium (gold standard); valproate (highly effective, teratogenic — cannot be used in women of childbearing age); lamotrigine (predominantly prevents depression); quetiapine; olanzapine.